Statin Use and Risk of Inflammatory Bowel Diseases: Authors' Reply
J Crohns Colitis
.
2021 Aug 2;15(8):1403-1404.
doi: 10.1093/ecco-jcc/jjab015.
Authors
Paul Lochhead
1
2
,
Hamed Khalili
1
2
,
Michael C Sachs
3
,
Andrew T Chan
1
2
,
Ola Olén
3
4
5
,
Jonas F Ludvigsson
6
7
Affiliations
1
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
2
Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
3
Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
4
Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
5
Sachs' Children and Youth Hospital, Stockholm South General Hospital, Stockholm, Sweden.
6
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
7
Department of Pediatrics, Örebro University Hospital, Örebro, Sweden.
PMID:
33474560
DOI:
10.1093/ecco-jcc/jjab015
No abstract available
Publication types
Editorial
Comment
MeSH terms
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Inflammatory Bowel Diseases* / drug therapy
Substances
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Grants and funding
Career Development Award
Crohn's and Colitis Foundation